CN114058598B - 新的重组杆状病毒基因组插入位点及其应用 - Google Patents
新的重组杆状病毒基因组插入位点及其应用 Download PDFInfo
- Publication number
- CN114058598B CN114058598B CN202111302847.1A CN202111302847A CN114058598B CN 114058598 B CN114058598 B CN 114058598B CN 202111302847 A CN202111302847 A CN 202111302847A CN 114058598 B CN114058598 B CN 114058598B
- Authority
- CN
- China
- Prior art keywords
- bev
- site
- mcherry
- coding region
- recombinant baculovirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000701447 unidentified baculovirus Species 0.000 title claims abstract description 50
- 238000003780 insertion Methods 0.000 title abstract description 32
- 230000037431 insertion Effects 0.000 title abstract description 32
- 230000014509 gene expression Effects 0.000 claims abstract description 44
- 108700008625 Reporter Genes Proteins 0.000 claims abstract description 29
- 208000015181 infectious disease Diseases 0.000 claims abstract description 26
- 108091092724 Noncoding DNA Proteins 0.000 claims abstract description 16
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 claims abstract description 12
- 108091006047 fluorescent proteins Proteins 0.000 claims abstract description 12
- 102000034287 fluorescent proteins Human genes 0.000 claims abstract description 11
- 108700026244 Open Reading Frames Proteins 0.000 claims abstract description 8
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 108091029865 Exogenous DNA Proteins 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 27
- 108020004414 DNA Proteins 0.000 abstract description 18
- 239000012634 fragment Substances 0.000 abstract description 10
- 238000005215 recombination Methods 0.000 abstract description 8
- 230000006798 recombination Effects 0.000 abstract description 7
- 230000010076 replication Effects 0.000 abstract description 4
- 241000709691 Enterovirus E Species 0.000 description 52
- 239000013612 plasmid Substances 0.000 description 12
- 241000238631 Hexapoda Species 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 108010054624 red fluorescent protein Proteins 0.000 description 10
- 241000700605 Viruses Species 0.000 description 8
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 229960005091 chloramphenicol Drugs 0.000 description 5
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 108020004638 Circular DNA Proteins 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 101000740205 Homo sapiens Sal-like protein 1 Proteins 0.000 description 4
- 101100442582 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) spe-1 gene Proteins 0.000 description 4
- 102100037204 Sal-like protein 1 Human genes 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- 108700039887 Essential Genes Proteins 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000000799 fluorescence microscopy Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 241000256251 Spodoptera frugiperda Species 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 101150075620 odv-e56 gene Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 241000537219 Deltabaculovirus Species 0.000 description 1
- 101100363961 Escherichia coli (strain K12) rseD gene Proteins 0.000 description 1
- 108010046276 FLP recombinase Proteins 0.000 description 1
- 241000219823 Medicago Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- 101710182846 Polyhedrin Proteins 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 101150047086 arm gene Proteins 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 208000030151 polycystic kidney disease 3 with or without polycystic liver disease Diseases 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明公开了新的可稳定携载外源基因的重组杆状病毒基因组插入位点及其应用,在杆状病毒AcMNPV的基因组中筛选和鉴定出合适的非编码区插入位点S1位点和S2位点,S1位点是开放阅读框Ac‑orf‑19与Ac‑arif‑1之间的223bp非编码区,S2位点是开发阅读框Ac‑PIF‑4与Ac‑38K之间的153bp非编码区,上述位点允许插入一定长度的外源基因片段而不影响BEV的复制且具有较好的传代稳定性,同时通过Red重组在重组杆粒DNA中上述位点插入荧光蛋白报告基因表达框,将新的重组杆粒转染Sf9细胞获得携带荧光蛋白报告基因的BEV,可方便的测定BEV的感染滴度的应用。
Description
技术领域
本发明属于病毒载体技术领域,更具体地,涉及一种重组杆状病毒表达系统中重组杆状病毒(BEV)基因组中能够允许外源基因稳定表达的新的插入位点及其应用。
背景技术
昆虫细胞表达系统(即重组杆状病毒表达系统)具有重组蛋白表达量高、蛋白翻译后修饰较为全面、适合大规模生产、生产成本较低等优势,已被广泛用于多种重组蛋白的表达、药物研发、药物和疫苗等的商业化生产。其中,重组杆状病毒(BEV)作为外源基因表达载体主要有以下优势:杆状病毒基因组相对较小易于操作,可容纳的外源基因片段较大、安全性高等。目前,重组杆状病毒(BEV)应用最广泛的是基于苜蓿银纹夜蛾核形多角体病毒(AcMNPV)基因组改造而来,AcMNPV基因组为双链环状DNA,全长133,966bp,序列和图谱参考(Maghodia等,Genome Announc,2014,2(6):e01202-14.),应用较为广泛昆虫细胞系是来自草地贪夜蛾(Spodoptera frugiperda)的Sf9细胞。
现有的重组杆状病毒表达系统中,其中被广泛采用的是Bac-to-Bac系统,该系统最早的开发者Luckow等选用杆状病毒的复制非必须基因多角体基因(Polyhedron,polh)位点作为Tn7转座子的重组位点,外源基因选择插入这个基因座通常能够获得很高的表达水平。其原理是:首先将外源基因构建到穿梭质粒中,接着将重组穿梭质粒转化含有重组杆粒的大肠杆菌,通过Tn7转座子介导的细菌水平重组将重组穿梭质粒携带的外源基因整合到重组杆粒中。然后从上述大肠杆菌中抽提获得的重组杆粒DNA转染昆虫细胞后拯救出携带有外源基因的重组杆状病毒BEV。该系统中这种既能在大肠杆菌中进行复制增殖又能在昆虫细胞中进行复制并包装出重组杆状病毒的大分子环状DNA被称为杆粒(Bacmid),其携带有细菌复制原点、抗生素抗性基因、重组杆状病毒基因组和Tn7重组克隆位点,便于重组杆状病毒的构建,AcMNPV Bacmid(bMON14272)的结构参考(Luckow等,J Virol,1993.67(8):4566-79.)。
有研究报道昆虫杆状病毒表达系统中的BEV在传代过程中,会产生并积累丢失部分基因的缺陷干扰病毒,导致外源基因表达下降(Pijlman等,J Gen Virol,2003,84:2669-78)。外源基因在BEV基因组中的不稳定因素,包括外源基因自身的不稳定性、插入DNA片段的负载、插入的位点以及不同细胞环境对缺陷病毒的选择性等(Willemsen等,Virus Evol,2019,5(2):vez045)。例如:制备重组腺相关病毒载体(rAAV)的不依赖Sf9包装细胞系的新型一杆状病毒(One Bac)系统中的BEV/Cap2-(ITR-GFP)-Rep稳定性在P4代后出现显著降低(Wu等,Mol Ther Methods Clin Dev,2018;10:38-47)。AcMNPV双链环状DNA基因组全长约134kbp,含有约150多个开放阅读框(ORF)和多种非编码的基因调节序列元件,目前仍有多种ORF的功能未知。在杆状病毒基因组中已经发现了多种允许异源基因高表达的复制非必须基因的基因座。Noad等发现了ctx、egt、39k、orf51、pg37、iap2、odv-e56非必须基因座(Noad等,2009,BMC Molecular Biology,10:87)。近期,有研究发现Bac to Bac系统中Tn7转座子由原来的polh位点置换到新的插入位点odv-e56基因座时,所获得的BEV能够高表达外源基因,尤其值得的注意的是该BEV连续传代的稳定性有显著增强(Pijlman等,J GenVirol,2003,84:2669-78),这非常有利于扩大感染Sf9细胞生产规模。然而,目前发现的这种能够插入较大外源基因后长期稳定传代的BEV基因组中的有效插入位点仍然很匮乏。
发明内容
针对现有技术的以上缺陷或改进需求,本发明一方面提供了新的可稳定携载外源基因的重组杆状病毒基因组插入位点,通过在杆状病毒AcMNPV的基因组中筛选和鉴定出合适的非编码区插入位点S1位点和S2位点,可以实现插入外源基因的BEV具有较高的连续传代稳定性,从而为杆状病毒表达系统中的BEV基因组中的有效插入位点提供新的选择。另一方面,提供了一种稳定性较高的携带荧光蛋白报告基因的BEV,可方便的测定BEV的感染滴度。
为实现上述目的,本发明采用以下技术方案:
重组杆状病毒:在重组杆状病毒AcMNPV基因组非编码区S1位点或S2位点插入外源DNA,S1位点是开放阅读框Ac-orf-19与Ac-arif-1之间的223bp非编码区,其核苷酸序列如SEQ ID NO.1所示,S2位点是开放阅读框Ac-PIF-4与Ac-38K之间的153bp非编码区,其核苷酸序列如SEQ ID NO.2所示。
一种稳定性较高的携带荧光蛋白报告基因的重组杆状病毒:在S1或S2位点插入荧光蛋白报告基因表达框。具体地,在本发明的具体实施例中插入红色荧光蛋白(mcherry)报告基因,报告基因表达框为ETL-mcherry-SV40pA:杆状病毒早晚期ETL启动子调控mcherry报告基因以及SV40pA元件,由于ETL属于早晚期启动子,可以在BEV感染Sf9细胞后,较早的时间启动mcherry的表达,缩短检测时间。
稳定性较高的携带荧光蛋白报告基因的重组杆状病毒在可视化检测重组杆状病毒感染滴度中的应用,包括以下步骤:
(1)构建含有表达荧光蛋白报告基因的表达框,该表达框两侧为S1或S2插入位点上下游同源臂;
(2)利用Red重组将荧光蛋白报告基因的表达框重组进上述插入位点,并获得重组病毒;
(3)将获得的BEV病毒,按照一定的比例梯度稀释后感染96孔板中培养的Sf9细胞;
(4)感染48h后,可通过荧光显微镜观察荧光报告基因的表达,测定rAAV的感染活性。与现有技术相比,本发明具有以下优点及有益效果:
1、本发明筛选获得的2个插入位点所在的非编码区序列,有一个共同的特点,均位于2个尾对尾的ORF终止密码子之间的序列。由于一般ORF终止密码子之后的序列,相比ORF起码密码子之前的序列,对于ORF的表达影响相当较小。这也可能是我们所选择的2个插入位点序列获得成功的原因之一。
2、相对于有些外源基因插入在非必须基因座,虽然不影响复制,但影响ODV的生成,导致不能利用BEV口服感染昆虫虫体,而在本发明提供的两个插入位点插入外源基因并不破坏原有基因组的构成,对BEV天然属性影响小,
3、在本发明提供的S1或S2位点插入红色荧光蛋白基因表达框后获得的重组杆状病毒连续传代多次(至少9代)后,荧光蛋白基因的表达仍然能够维持较高的水平,该重组杆状病毒可应用于快速可视化检测BEV的感染滴度。
附图说明
图1是本发明杆状病毒AcMNPV基因组插入位点S1和S2以及插入红色荧光蛋白mcherry报告基因表达框的示意图。左侧为AcMNPV重组杆粒基因组示意图,其中杆状病毒AcMNPV基因组为双链环状DNA,全长133,966bp。
图2是在杆状病毒基因组插入位点S1和S2插入红色荧光蛋白(mcherry)报告基因表达框,获得的重组杆状病毒BEV-S1-mcherry和BEV-S2-mcherry感染Sf9细胞后表达红色荧光的结果。
图3是实施例1和实施例2中获得的BEV-S1-mcherry和BEV-S2-mcherry连续传代稳定性测试结果。
图4是实施例1中获得的BEV-S1-mcherry梯度稀释感染Sf9细胞进行感染滴度测试的结果。
图5是实施例2中获得的BEV-S2-mcherry梯度稀释感染Sf9细胞进行感染滴度测试的结果。
具体实施方式
我们通过对杆状病毒AcMNPV基因组序列进行分析,选择了多个位点进行测试,最终优选出2个非编码区插入位点S1(对应于ORF Ac-orf-19与ORF Ac-arif-1之间的223bp非编码区序列,其核苷酸序列如SEQ ID NO.1所示)和S2(对应于ORF Ac-PIF-4与ORF Ac-38K之间的153bp非编码区序列,其核苷酸序列如SEQ ID NO.2所示)。
实施例1.构建S1插入位点表达报告基因mcherry的BEV
为了便于重组克隆操作,我们利用Red重组技术,使用转化有pKD46质粒并含有AcMNPV杆粒的大肠杆菌DH10Bac菌株,通过同源臂基因重组的方法来改造杆粒基因组。pKD46质粒是温度敏感型低拷贝质粒,在20~25℃条件下,加入阿拉伯糖可以诱导Exo、Beta和Gam这3种蛋白(即Red重组酶)的表达,能够将携带有同源臂的外源基因与细菌中的杆粒基因组进行高效的特异性重组(参考Doublet等,2008,J Microbiol Methods.,75(2):359-61)。为了便于重组子的筛选,引入两侧带有Frt序列的氯霉素(Chloromycetin,Chlo)抗性基因(用引物从PKD3质粒上扩增片段P1-FRT-Chlo-P2,序列如SEQ ID NO.3所示),便于随后通过Flp重组酶的作用去除该抗性基因。
本实施例中选用杆状病毒早晚期ETL启动子调控红色荧光蛋白(mcherry)报告基因,加上SV40PA元件的表达框mcherry报告基因的表达框为ETL-mcherry-SV40pA,优选SEQID NO.4所示的序列。由于ETL属于早期至晚期启动子,可以在BEV感染Sf9细胞后,较早的时间启动mcherry的表达,缩短检测时间。具体方法如下:
我们利用pBluescriptII KS(+)质粒骨架进行构建,在pBlue质粒的Sal1和Spe1酶切位点之间引入人工合成的上游同源臂S1-Up(如SEQ ID NO.5所示的序列)和下游同源臂S1-Down(如SEQ ID NO.6所示的序列),然后将氯霉素抗性基因片段P1-FRT-Chlo-P2和mcherry报告基因的表达框ETL-mcherry-SV40pA插入到上下同源臂的中间。通过多片段重组克隆的方法,构建质粒pBlue-S1-Up-P1-FRT-Chlo-P2-mcherry-S1-Down。然后用Sal1和Spe1双酶切,电泳回收S1-Up-P1-FRT-Chlo-P2-mcherry-S1-Down核酸片段。然后,将该DNA片段电转化DH10Bac/pKD46感受态细胞,涂卡那霉素、四环素、氯霉素三种抗性的LB平板。电转48h后,挑取蓝斑摇菌。小提杆粒DNA进行PCR鉴定,筛选阳性克隆,测序验证。我们将筛选出来的阳性菌株命名为DH10Bac-S1-mcherry。该菌中就含有了在S1插入位点携带mcherry报告基因的表达框ETL-mcherry-SV40pA的重组杆状病毒基因组的重组杆粒。
按照Bac-to-Bac系统的操作方法制备BEV,抽提该重组杆粒DNA转染Sf9昆虫细胞,制备重组杆状病毒BEV-S1-mcherry。转染后的Sf9昆虫细胞成功产生BEV,大量复制增殖的BEV进一步感染导致Sf9细胞发生明显病变现象(CPE),用荧光显微镜可以观察大明显的红色荧光蛋白(mcherry)的表达(图2)。收集发生CPE的Sf9细胞培养上清液,其中含有大量BEV,即为第1代BEV(P1)。结果表明我们成功构建获得了在S1插入位点表达报告基因mcherry的BEV-S1-mcherry。
实施例2.构建S2插入点表达报告基因mcherry的BEV
同实施例1所述,在pBlue质粒的Sal1和Spe1酶切位点之间引入人工合成的上游同源臂S2-Up(如SEQ ID NO.7所示的序列)和下游同源臂S2-Down(如SEQ ID NO.8所示的序列),然后将氯霉素抗性基因片段P1-FRT-Chlo-P2和mcherry报告基因的表达框为ETL-mcherry-SV40pA插入到上下同源臂的中间。构建质粒pBlue-S2-Up-P1-FRT-Chlo-P2-mcherry-S2-Down。然后用Sal1和Spe1双酶切,电泳回收S2-Up-P1-FRT-Chlo-P2-mcherry-S2-Down核酸片段。然后,将该DNA片段电转化DH10Bac/pKD46感受态细胞,涂卡那霉素、四环素、氯霉素三种抗性的LB平板。电转48h后,挑取蓝斑摇菌。小提杆粒DNA进行PCR鉴定,筛选阳性克隆,测序验证。我们将筛选出来的阳性菌株命名为DH10Bac-S2-mcherry。该菌中就含有了在S2插入位点携带mcherry报告基因的表达框ETL-mcherry-SV40pA的重组杆状病毒基因组的重组杆粒。
按照Bac-to-Bac系统的操作方法制备BEV,抽提该重组杆粒DNA转染Sf9昆虫细胞,制备重组杆状病毒BEV-S2-mcherry。转染后的Sf9昆虫细胞成功产生BEV,大量复制增殖的BEV进一步感染导致Sf9细胞发生明显病变现象(CPE),用荧光显微镜可以观察大明显的mcherry的表达(图2)。收集发生CPE的Sf9细胞培养上清液,其中含有大量BEV,即为第1代BEV(P1)。结果表明我们成功构建获得了在S2插入位点表达报告基因mcherry的BEV-S2-mcherry。
实施例3.检测S1和S2插入位点表达报告基因mcherry的BEV传代稳定性
实施例1和2中制备的BEV(P1)分别经过连续感染Sf9细胞传代9次,制备BEV(P2)至BEV(P9)。实验过程如下:首先,我们将制备得到的BEV(P1)以感染复数(MOI=0.1)感染6孔板中培养的Sf9细胞(约70%汇合度),感染3天后,将细胞培养液3000rpm离心5min,收集细胞培养上清液,即为第2代BEV(P2)。然后重复上述感染过程,获得BEV(P3)至BEV(P9)。
我们将BEV(P1-P9)分别感染96孔板中培养的Sf9细胞(约70%汇合度),感染2天后,通过荧光显微镜观测红色荧光蛋白(mcherry)的表达的情况,测试重组杆状病毒BEV的稳定性。为了便于对比,我们也按照文献(Wu等,Mol Ther Methods Clin Dev,2018;10:38-47)制备了BEV/Cap2-(ITR-GFP)-Rep的P1-P9代病毒。相比基于在非必须基因多角体基因(Polyhedron,polh)位点通过Tn7转座子重组构建得到的BEV/Cap2-(ITR-GFP)-Rep在P5代之后GFP的表达水平出现显著下降(图3),而重组杆状病毒BEV-S1-mcherry和BEV-S2-mcherry的P1-P9病毒代感染Sf9细胞后,红色荧光蛋白(mcherry)的表达都维持了较高的水平,BEV稳定性得到了较大程度的提高(图3)。综上,实验结果表明BEV-S1-mcherry和BEV-S2-mcherry在P1-P9代稳定性较好,在BEV基因组的S1和S2位点允许插入一定长度的外源基因片段而不影响BEV的复制且具有较好的传代稳定性。
实施例4.利用表达报告基因mcherry测试BEV的感染滴度
我们将上述实施例中获得的BEV-S1-mcherry(P1)和BEV-S2-mcherry(P1)按10μL的起始感染体积进行10倍梯度稀释,然后分别感染96孔板中培养的Sf9细胞(约70%汇合度),感染2天后,利用荧光显微镜观察并拍照记录红色荧光蛋白(mcherry)的表达。我们可以观察到没有感染的Sf9细胞对照孔中不表达红色荧光蛋白,而随着BEV-S1-mcherry(P1)和BEV-S2-mcherry(P1)梯度稀释感染滴度的降低,96孔板中被感染的表达mcherry的Sf9细胞数目呈一定的梯度比例减少,红色荧光亮度也有所降低;直至出现某一个稀释度的96孔板中只有少量几个表达mcherry的Sf9细胞,而下一个稀释度的96孔板中没有表达mcherry的Sf9细胞(图4和图5)。我们可以通过统计某一个高稀释度的96孔板中只有少量几个表达mcherry的Sf9细胞数目,以及该96孔所对应的BEV稀释倍数和起始感染BEV的体积,综合计算出待测BEV的滴度,以病毒的荧光灶单位(FFU/ml)来表示。经过计算本实施例中所获得的BEV-S1-mcherry(P1)和BEV-S2-mcherry(P1)的滴度分别约为2.4E+9FFU/ml和8.5E+8FFU/ml。由此可见,在重组杆状病毒基因组S1和S2位点插入荧光蛋白报告基因表达框获得的BEV,可应用于快速方便地测定BEV的感染滴度。
本领域的技术人员容易理解,以上所述仅为本发明的较佳实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内所作的任何修改、等同替换和改进等,均应包含在本发明的保护范围之内。
序列表
<110> 中国科学院精密测量科学与技术创新研究院
<120> 新的重组杆状病毒基因组插入位点及其应用
<160> 8
<170> SIPOSequenceListing 1.0
<210> 1
<211> 223
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 1
aaataaataa ataaacttgt tcagttctaa ttattgtttt attttttata aaataataca 60
attttattta tacattaata ctttggtatt tattaataca attatttaca atactttatt 120
tacactataa tactttattt acattagtac taaattaata ctaaattacg ctaatactaa 180
attaatactt tatataatca aaaaatactt tatataatac ttt 223
<210> 2
<211> 153
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 2
cgcgtatata gacgcttgta cgttcatcgt agtaatcatt ttaatacatt tgattgaact 60
aaacatacat ctgcaatggg tgaaagagtc actaaatttt gcaatggaaa acggcgataa 120
agaagacagc gacaatgaat agagtttata ttt 153
<210> 3
<211> 1033
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 3
atgggaatta gccatggtcc atatgaatat cctccttagt tcctattccg aagttcctat 60
tctctagaaa gtataggaac ttcggcgcgc ctacctgtga cggaagatca cttcgcagaa 120
taaataaatc ctggtgtccc tgttgatacc gggaagccct gggccaactt ttggcgaaaa 180
tgagacgttg atcggcacgt aagaggttcc aactttcacc ataatgaaat aagatcacta 240
ccgggcgtat tttttgagtt gtcgagattt tcaggagcta aggaagctaa aatggagaaa 300
aaaatcactg gatataccac cgttgatata tcccaatggc atcgtaaaga acattttgag 360
gcatttcagt cagttgctca atgtacctat aaccagaccg ttcagctgga tattacggcc 420
tttttaaaga ccgtaaagaa aaataagcac aagttttatc cggcctttat tcacattctt 480
gcccgcctga tgaatgctca tccggaatta cgtatggcaa tgaaagacgg tgagctggtg 540
atatgggata gtgttcaccc ttgttacacc gttttccatg agcaaactga aacgttttca 600
tcgctctgga gtgaatacca cgacgatttc cggcagtttc tacacatata ttcgcaagat 660
gtggcgtgtt acggtgaaaa cctggcctat ttccctaaag ggtttattga gaatatgttt 720
ttcgtctcag ccaatccctg ggtgagtttc accagttttg atttaaacgt ggccaatatg 780
gacaacttct tcgcccccgt tttcaccatg ggcaaatatt atacgcaagg cgacaaggtg 840
ctgatgccgc tggcgattca ggttcatcat gccgtttgtg atggcttcca tgtcggcaga 900
tgcttaatga atacaacagt actgcgatga gtggcagggc ggggcgtaag gcgcgccatt 960
taaatgaagt tcctattccg aagttcctat tctctagaaa gtataggaac ttcgaagcag 1020
ctccagccta cac 1033
<210> 4
<211> 1555
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 4
aaataaataa ataaacttgt tcagttctaa ttattgtttt attttttata aaataataca 60
attttattta tacattaata ctttggtatt tattaataca attatttaca ataagccaca 120
ctggacacga aaaagtcgaa ggcactcgct tcgatcaatg gacaaagaat caatcgttcg 180
taggcaacag aatgtcggaa agtttgcatt ggatgcgcgg cgggtccaac ttgccgcaaa 240
actgcggcga gttcaacgtg gtgtccagcc tgttgatgtg caacaatacg ataatgaaaa 300
attgataacg cttgcacgat tgcaaacatg cacgctcggt tgaataaaag ctcgcatcgt 360
cgtcgtaaaa ttagttgtat caaagagcag ctgcaattag aatcactgct aaaaatgata 420
gatcggatcc atggtgagca agggcgagga ggataacatg gccatcatca aggagttcat 480
gcgcttcaag gtgcacatgg agggctccgt gaacggccac gagttcgaga tcgagggcga 540
gggcgagggc cgcccctacg agggcaccca gaccgccaag ctgaaggtga ccaagggtgg 600
ccccctgccc ttcgcctggg acatcctgtc ccctcagttc atgtacggct ccaaggccta 660
cgtgaagcac cccgccgaca tccccgacta cttgaagctg tccttccccg agggcttcaa 720
gtgggagcgc gtgatgaact tcgaggacgg cggcgtggtg accgtgaccc aggactcctc 780
cctgcaggac ggcgagttca tctacaaggt gaagctgcgc ggcaccaact tcccctccga 840
cggccccgta atgcagaaga agaccatggg ctgggaggcc tcctccgagc ggatgtaccc 900
cgaggacggc gccctgaagg gcgagatcaa gcagaggctg aagctgaagg acggcggcca 960
ctacgacgct gaggtcaaga ccacctacaa ggccaagaag cccgtgcagc tgcccggcgc 1020
ctacaacgtc aacatcaagt tggacatcac ctcccacaac gaggactaca ccatcgtgga 1080
acagtacgaa cgcgccgagg gccgccactc caccggcggc atggacgagc tgtactaatc 1140
tagagcctgc agtctcgaca agcttgtcga gaagtactag aggatcataa tcagccatac 1200
cacatttgta gaggttttac ttgctttaaa aaacctccca cacctccccc tgaacctgaa 1260
acataaaatg aatgcaattg ttgttgttaa cttgtttatt gcagcttata atggttacaa 1320
ataaagcaat agcatcacaa atttcacaaa taaagcattt ttttcactgc attctagttg 1380
tggtttgtcc aaactcatca atgtatctta tcatgtctgg atctgatcac tgcttgagcc 1440
taggacttta tttacactat aatactttat ttacattagt actaaattaa tactaaatta 1500
cgctaatact aaattaatac tttatataat caaaaaatac tttatataat acttt 1555
<210> 5
<211> 300
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 5
cactgttcaa atgcgcacgc aaaacaaacc cttgcaactt tatttgccaa tcgtaatcac 60
agtagttttt acgagtacgc catcgcgttt gtaagcacat tgctttttaa aaataattta 120
aatttaatga ccgcgtgcaa tttgatcaac tcgttgatca actttgaact caacatgttt 180
ggtaaaagtt tattgctaaa tggatttgtt aatttctgca ttgctaacag cgacggggtt 240
acgattcaac ataaaatgtt aaccaacgtg ttaagttttt tgttggaaaa atattattaa 300
<210> 6
<211> 300
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 6
ctaatcatca taaacgggta atagtttttt ctcttgaaat ttacgctgca actcttcgct 60
aaaacacatg ggcggtggag tgggagcggg tggagtagga gtccttacgg gtttgatggg 120
cgacagttct ctggacttgc ggaacagctt gggcgaaagc gtcggcgtgc gccgactaat 180
gatttcttca tccggcaacg gaggctcgca cattgtgcac gcgtccggtg aggtacacaa 240
aactttcttg ggcacgctgt acaccggctt gggcacgcta tatgtgttgc caaaatagaa 300
<210> 7
<211> 300
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 7
aattttaaca aaacgctcta ttattacttg gactcggcga acgtgttttg tcccaacgag 60
tttagcgtga ccacgttcac gcaatccact attaaaacga tcaacgagac gggaatatat 120
gccaccgcat gcacgccggt cagcagcttg acgctaattg aacattttgc aacattaaaa 180
aataacgtgc ccgatcacac gctcgttctc gatgtggtcg accaacagat tcagttttca 240
atactcgaca ttatcaatta tttgatttac aatggctacg tggatttgtt ggccgaataa 300
<210> 8
<211> 300
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 8
ttatttaata aaatattgtt cgtaatccat aatgttttgt attatttcat tgtgataatg 60
ttcccaatct tgcacggggg tggggcatcg tttgactttg acgtagaaat cgtacgcgta 120
gttattagtt ggcagatcgt cgacaagtgt gatcgacttg aaaaagttta catttttatc 180
gctcaaatat ttaattacaa tttttggcga tttgggtata ttgttgtcgg atcgatgatt 240
gtgaatgtca aaaacaaatt tattttcaat gaaacgcttt tttaaattgt aatctacaat 300
Claims (4)
1.重组杆状病毒,其特征在于,在重组杆状病毒AcMNPV基因组非编码区S1位点或S2位点插入外源DNA,S1位点是开放阅读框Ac-orf-19与Ac-arif-1之间的223bp非编码区,其核苷酸序列如SEQ ID NO.1所示,S2位点是开放阅读框Ac-PIF-4与Ac-38K之间的153bp非编码区,其核苷酸序列如SEQ ID NO.2 所示。
2.根据权利要求1所述的重组杆状病毒,其特征在于,在S1或S2位点插入荧光蛋白报告基因表达框。
3.根据权利要求2所述的重组杆状病毒,其特征在于,所述表达框采用杆状病毒早晚期ETL启动子调控荧光蛋白报告基因以及SV40pA序列。
4.权利要求3所述的重组杆状病毒在可视化检测重组杆状病毒感染滴度中的应用。
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111302847.1A CN114058598B (zh) | 2021-11-04 | 2021-11-04 | 新的重组杆状病毒基因组插入位点及其应用 |
| PCT/CN2021/128987 WO2023077424A1 (zh) | 2021-11-04 | 2021-11-05 | 新的重组杆状病毒基因组插入位点及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111302847.1A CN114058598B (zh) | 2021-11-04 | 2021-11-04 | 新的重组杆状病毒基因组插入位点及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114058598A CN114058598A (zh) | 2022-02-18 |
| CN114058598B true CN114058598B (zh) | 2023-04-28 |
Family
ID=80273992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111302847.1A Active CN114058598B (zh) | 2021-11-04 | 2021-11-04 | 新的重组杆状病毒基因组插入位点及其应用 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN114058598B (zh) |
| WO (1) | WO2023077424A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118086400B (zh) * | 2024-04-17 | 2024-07-19 | 和元生物技术(上海)股份有限公司 | 核酸分子、包含其的重组杆状病毒及其应用 |
Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5077214A (en) * | 1989-07-07 | 1991-12-31 | The Texas A&M University System | Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells |
| US5162222A (en) * | 1989-07-07 | 1992-11-10 | Guarino Linda A | Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses |
| US5169784A (en) * | 1990-09-17 | 1992-12-08 | The Texas A & M University System | Baculovirus dual promoter expression vector |
| WO1996001320A2 (en) * | 1994-07-04 | 1996-01-18 | Natural Environment Research Council | Complete genomic sequence of autographa californica nuclear polyhedrosis virus c6 |
| CN1570121A (zh) * | 2003-07-25 | 2005-01-26 | 北京三诺佳邑生物技术有限责任公司 | 高效生产重组腺病毒伴随病毒的病毒载体、细胞系、方法及其组成的生产系统 |
| CN102686732A (zh) * | 2009-08-17 | 2012-09-19 | 吉尼松公司 | 基于杆状病毒生产不含污染性杆状病毒毒粒的生物药品 |
| CN106497974A (zh) * | 2016-09-23 | 2017-03-15 | 广西壮族自治区药用植物园 | 可快速测定滴度的杆状病毒表达载体及其构建和应用 |
| CN106544325A (zh) * | 2015-09-23 | 2017-03-29 | 中国科学院武汉物理与数学研究所 | 一种重组杆状病毒及其应用 |
| CN106987603A (zh) * | 2016-01-20 | 2017-07-28 | 中国科学院武汉物理与数学研究所 | 一种重组腺相关病毒的制备方法 |
| CN109609552A (zh) * | 2018-12-28 | 2019-04-12 | 中国科学院武汉物理与数学研究所 | 重组腺相关病毒的制备方法、系统及重组杆粒 |
| CN112553257A (zh) * | 2020-12-03 | 2021-03-26 | 武汉枢密脑科学技术有限公司 | 一种重组腺相关病毒的制备方法、系统及重组杆粒 |
| CN113073117A (zh) * | 2021-04-13 | 2021-07-06 | 陕西杆粒生物科技有限公司 | 一种Ac18-23敲除的杆状病毒表达载体 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9267113B2 (en) * | 2014-03-10 | 2016-02-23 | Chung Yuan Christian University | Hybrid baculovirus and uses thereof |
| CN105002132B (zh) * | 2015-08-19 | 2018-05-29 | 中国科学院武汉病毒研究所 | 一种在多种昆虫细胞表达外源蛋白的Ⅱ组甲型杆状病毒Bacmid及应用 |
| US11708585B2 (en) * | 2018-12-28 | 2023-07-25 | Wuhan Institute Of Physics And Mathematics, Chinese Academy Of Sciences | Method, system and recombinant bacmid for preparation of recombinant adeno-associated virus |
-
2021
- 2021-11-04 CN CN202111302847.1A patent/CN114058598B/zh active Active
- 2021-11-05 WO PCT/CN2021/128987 patent/WO2023077424A1/zh not_active Ceased
Patent Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5077214A (en) * | 1989-07-07 | 1991-12-31 | The Texas A&M University System | Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells |
| US5162222A (en) * | 1989-07-07 | 1992-11-10 | Guarino Linda A | Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses |
| US5169784A (en) * | 1990-09-17 | 1992-12-08 | The Texas A & M University System | Baculovirus dual promoter expression vector |
| WO1996001320A2 (en) * | 1994-07-04 | 1996-01-18 | Natural Environment Research Council | Complete genomic sequence of autographa californica nuclear polyhedrosis virus c6 |
| CN1570121A (zh) * | 2003-07-25 | 2005-01-26 | 北京三诺佳邑生物技术有限责任公司 | 高效生产重组腺病毒伴随病毒的病毒载体、细胞系、方法及其组成的生产系统 |
| CN102686732A (zh) * | 2009-08-17 | 2012-09-19 | 吉尼松公司 | 基于杆状病毒生产不含污染性杆状病毒毒粒的生物药品 |
| CN106544325A (zh) * | 2015-09-23 | 2017-03-29 | 中国科学院武汉物理与数学研究所 | 一种重组杆状病毒及其应用 |
| CN106987603A (zh) * | 2016-01-20 | 2017-07-28 | 中国科学院武汉物理与数学研究所 | 一种重组腺相关病毒的制备方法 |
| CN106497974A (zh) * | 2016-09-23 | 2017-03-15 | 广西壮族自治区药用植物园 | 可快速测定滴度的杆状病毒表达载体及其构建和应用 |
| CN109609552A (zh) * | 2018-12-28 | 2019-04-12 | 中国科学院武汉物理与数学研究所 | 重组腺相关病毒的制备方法、系统及重组杆粒 |
| CN112553257A (zh) * | 2020-12-03 | 2021-03-26 | 武汉枢密脑科学技术有限公司 | 一种重组腺相关病毒的制备方法、系统及重组杆粒 |
| CN113073117A (zh) * | 2021-04-13 | 2021-07-06 | 陕西杆粒生物科技有限公司 | 一种Ac18-23敲除的杆状病毒表达载体 |
Non-Patent Citations (2)
| Title |
|---|
| Yang Wu等.A Recombinant Baculovirus Efficiently Generates Recombinant Adeno-Associated Virus Vectors in Cultured Insect Cells and Larvae.《Mol Ther Methods Clin Dev》.2018,第10卷第38-47页. * |
| Yang Wu等.Development of Versatile and Flexible Sf9 Packaging Cell Line-Dependent OneBac System for Large-Scale Recombinant Adeno-Associated Virus Production.《Hum Gene Ther Methods》.2019,第30卷(第5期),第172-183页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114058598A (zh) | 2022-02-18 |
| WO2023077424A1 (zh) | 2023-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7134240B2 (ja) | 組換え型アデノ随伴ウイルスの調製方法、システム及び組換え型バクミド | |
| US12344856B2 (en) | Preparation method and system for recombinant adeno-associated virus, and recombinant bacmid | |
| CN103827306B (zh) | 用于基因治疗载体的表达的杆状病毒系统 | |
| CN112143712A (zh) | 一种重组腺相关病毒及其制备方法和在抗体检测的应用 | |
| US20250066811A1 (en) | DNA Amplification Method Using CARE Elements | |
| CN114058598B (zh) | 新的重组杆状病毒基因组插入位点及其应用 | |
| US11732276B2 (en) | Use of genomic NW_006882077.1 in CHO cell for stably expressing a protein | |
| CN113355292A (zh) | 一种猪圆环病毒基因改造型弱毒株、构建方法及其应用 | |
| CN103352050B (zh) | 利用细菌人工染色体同源重组提高细胞转染效率的方法 | |
| KR101029972B1 (ko) | 바이러스 벡터를 이용하여 단백질의 상호작용을 측정하는 방법 | |
| US11708585B2 (en) | Method, system and recombinant bacmid for preparation of recombinant adeno-associated virus | |
| CN113061625A (zh) | 一种复制缺陷型犬细小病毒包装载体、复制缺陷型重组犬细小病毒及制备与应用 | |
| CN117051046B (zh) | 一种慢病毒载体及其应用 | |
| CN102286534A (zh) | 表达多外源基因的昆虫生物反应器及其构建方法和应用 | |
| CN118562888A (zh) | 一种重组杆粒制备系统及BmNPV-rAAV重组杆粒 | |
| CN118086400B (zh) | 核酸分子、包含其的重组杆状病毒及其应用 | |
| EP4520818A1 (en) | Baculovirus vector and use thereof in preparation of raav in insect cell | |
| JP7784694B2 (ja) | ウイルス感染を評価する方法 | |
| CN115927470B (zh) | 腺病毒包装用系统、应用及腺病毒包装方法 | |
| CA3123692C (en) | Method and system for preparing recombinant adeno-associated virus, and recombinant bacmid | |
| WO2023221240A1 (zh) | 一种用于昆虫细胞中产生重组杆状病毒的组合物、方法及应用 | |
| CN120775918A (zh) | Tp63基因在提高外源重组蛋白表达量中的应用 | |
| CN112143756A (zh) | 一种基于AdEasyTM系统的高效重组腺病毒载体的制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |